Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Capital Leases (2016 - 2018)

Historic Capital Leases for Ironwood Pharmaceuticals (IRWD) over the last 10 years, with Q4 2018 value amounting to $158000.0.

  • Ironwood Pharmaceuticals' Capital Leases changed N/A to $158000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $158000.0, marking a year-over-year change of. This contributed to the annual value of $158000.0 for FY2018, which is N/A changed from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Capital Leases of $158000.0 as of Q4 2018.
  • Ironwood Pharmaceuticals' 5-year Capital Leases high stood at $3.2 million for Q2 2014, and its period low was $21000.0 during Q1 2017.
  • In the last 5 years, Ironwood Pharmaceuticals' Capital Leases had a median value of $687000.0 in 2015 and averaged $1.3 million.
  • Per our database at Business Quant, Ironwood Pharmaceuticals' Capital Leases skyrocketed by 149494.95% in 2014 and then plummeted by 9169.96% in 2017.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Capital Leases stood at $2.6 million in 2014, then plummeted by 88.1% to $306000.0 in 2015, then tumbled by 73.2% to $82000.0 in 2016, then crashed by 74.39% to $21000.0 in 2017, then soared by 652.38% to $158000.0 in 2018.
  • Its Capital Leases stands at $158000.0 for Q4 2018, versus $21000.0 for Q1 2017 and $82000.0 for Q4 2016.